Healthcare / Medical DevicesASX
$0.11
-0.01 (-4.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-9.4M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$102M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-116.7%
↓Gross Margin
63.2%
↑Debt/Equity
1.13
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.4%
FCF CAGR
—
FCF margin
-75.1%
FCF / Net income
1.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $12.5M · net income $-7.2M · FCF $-9.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $12.5M | $12.5M | $11.1M | $10.5M | $11.6M |
| Net Income | $-7.2M | $-7.2M | $-8.6M | $-9.0M | $-45.7M |
| EBITDA | $-4.6M | $-4.6M | $-5.4M | $-4.9M | $-42.7M |
| EPS | -0.01 | -0.01 | -0.02 | -0.04 | -0.28 |
| Gross Margin | 63.2% | 63.2% | 63.8% | 56.7% | 38.3% |
| Operating Margin | -62.7% | -62.7% | -64.0% | -90.4% | -181.2% |
| Net Margin | -57.5% | -57.5% | -77.2% | -85.2% | -393.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.13 | 1.13 | 1.13 | 1.03 | 0.40 |
| Current Ratio | 0.73 | 0.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.4M | $-9.4M | $848000.00 | $-9.8M | $-22.4M |
| Returns | |||||
| ROE | -116.7% | -116.7% | -120.9% | -94.5% | -255.7% |
| Valuation | |||||
| P/B | 12.15 | 12.15 | 2.71 | 2.27 | 1.50 |
| Growth & Yield | |||||
| Revenue Growth | 12.3% | 12.3% | 5.7% | -9.4% | — |
| EPS Growth | 38.9% | 38.9% | 51.6% | 87.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+254.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.01
Residual
+254.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.